Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -

- Cash, cash equivalents, and marketable securities of $296.3 million at Q2 2025; runway through at least 2027 -

Read more at prnewswire.com